Board summary
Key figures
49,741
Registered population
61.3% aged 18–64
12.4%
Aged 65+
ICB 14.9% · England 17.9%
35.2%
Ethnic minority (non-White)
10.1% Asian · England 9.6%
88.2%
In IMD quintile 1
ICB 40.7% · England 21.0%
~39,281
Core20 residents (est.)
Resident basis; registered basis ~44,972 · see page 3
7,103
Hypertension register
+4.37% in 3 yrs · England +5.60%
749
SMI register
7.9% of Manchester (LAD)'s
1,573
COPD register
Reviews -2.04% in 3 yrs
Forecast to 2030
7,978
Hypertension patients, 2030
+875 on today
77.7%
QRISK ≥20% on statins, 2030
+1.84pp over 3 yrs
3.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Pre-school booster and MMR2 uptake lag behind England.
Age-5 4-in-1 booster coverage is 70.4% (24.6 pp below the 95.0% target) and MMR2 is 76.1%, which may reflect recall gaps (unverified locally).
Non-frail diabetes HbA1c control trails national growth.
HbA1c control (<= 58 mmol/mol) is 53.6% (1,484 of 2,767; England 57.4%), growing +0.9% over 2023 to 2025 (England +4.4%).
Preventive lipid and diabetes statin prescribing exceed England.
Lipid-lowering therapy reaches 73.9% of QRISK ≥ 20% patients (England 63.6%), alongside 81.7% primary and 89.4% secondary statin coverage in diabetes.
Population, age and ethnicity
Children comprise 26.3% of registered patients while ethnic minority resident share reaches 35.2%
The PCN serves 49,741 registered patients across its practices. Children aged 0-17 represent 26.3% (13,085 patients), exceeding Manchester (LAD) (21.4%), NHS Greater Manchester ICB (21.8%) and England (19.6%). Patients aged 65+ comprise 12.4% (6,174 patients; England 17.9%). Local Census residents show a 35.2% ethnic minority share, including 18.1% Black / African / Caribbean / Black British (Manchester (LAD) 11.9%, England 4.2%), led by Church View Medical Centre (29.3%) and Fernclough Surgery (27.7%). Resident ethnicity differs from registered patient lists.
Age profile
65+: ICB 14.9%, England 17.9%
Ethnicity
Older people · falls rows are Manchester (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Manchester LA) | 2,357 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.5% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 53.6% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Manchester LA) | 1,281 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Manchester LA) | 26.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 areas house 88.2% of registered patients, requiring dual concentration and volume targeting
Across the PCN, 88.2% of registered patients live in Core20 areas, exceeding Manchester (LAD) (59.8%), NHS Greater Manchester ICB (40.7%) and England (21.0%), with an average IMD decile of 1.8. Church View Medical Centre, Fernclough Surgery and Willowbank Surgery each have a 100.0% Core20 share, while The Avenue Medical Centre (estimated 9,587) and Valentine Medical Centre (estimated 9,287) hold the largest Core20 volumes. Weighted practice share is 90.4%, requiring baseline reconciliation. Resources may need dual deployment between saturated full-share practices and high-volume lists.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
749
SMI register
1.46% recorded prevalence
463
Learning disability register
0.91% recorded prevalence
19
Care homes, 500 beds
In the PCN catchment
8.7%
Provide unpaid care
Manchester (LAD), Census 2021
Recorded severe mental illness prevalence is 1.5% (749 patients) and learning disability prevalence is 0.9% (463 patients), both exceeding Manchester (LAD) (1.3%; 0.7%), NHS Greater Manchester ICB (1.1%; 0.6%) and England (1.0%; 0.6%). The catchment also includes 19 care homes with 500 beds. Higher recorded registers indicate substantial review cohorts, though care-home bed capacity does not establish resident patient numbers.
Severe mental illness: physical health checks
SMI prevalence is 1.5% (England 1.0%). Recorded blood pressure is 84.8% (England 83.4%) and BMI is 85.9% (England 82.1%). Smoking cessation offers fell 0.4 pp over 2023 to 2025 (England +0.1 pp); missing elements cannot imply completed full checks.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,103
Hypertension register
+4.37%
Register growth, 3 yrs
Manchester (LAD) +4.49% · England +5.60%
+3.83pp
BP control, under 80
≤140/90 · +2.42pp aged 80+
+875
More patients by 2030
Forecast 7,978 (15.12%)
Hypertension case-finding and control
Recorded hypertension prevalence is 13.9% (7,103 patients; crude rate unadjusted for age), below England (15.2%) and NHS Greater Manchester ICB (14.4%), but above Manchester (LAD) (10.5%), with 3-year register growth of +4.4% (2023 to 2025) trailing England (+5.6%). Although recent blood pressure checks reach 91.0% (England 90.0%), treatment to target stands at 69.1%, behind England (70.3%) and the ICB (71.4%). In parallel, HbA1c control (<= 58 mmol/mol) in non-frail diabetes is 53.6% (1,484 of 2,767; England 57.4%), which could reflect titration bottlenecks (unverified locally; a medication review would test this). Treatment to target lags England despite high monitoring reach, highlighting a priority to intensify medication titration and clinical recall for uncontrolled patients.
Lipids and statins
Lipid-lowering therapy reaches 73.9% of patients with QRISK ≥ 20% (England 63.6%; ICB 67.0%), while statin therapy reaches 81.7% in diabetes without CVD (England 73.2%) and 89.4% with CVD (England 84.4%). Higher uptake than England demonstrates strong preventive prescribing, meaning practices should focus on sustaining long-term therapy adherence.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 103,348 | £2.00 | £1.94 | £1.86 | £206,696 |
| Cardiovascular (all), 2025 | 143,240 | £2.41 | £3.15 | £3.33 | £345,208 |
In 2026, the PCN prescribed 103,348 lipid-modifying items at £2.00 per item (£206,696 total spend), compared with £1.86 in England and £1.94 in NHS Greater Manchester ICB, spending £14,469 more than at England's unit cost. Higher unit costs than England may reflect formulary mix differences rather than inefficiency (unverified locally; a prescribing audit would test this).
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+3.07%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.49%
Asthma prevalence, PCN 3-yr % change
Recorded COPD prevalence reached 3.1% (1,573 patients), growing +10.2% over 2023 to 2025 (England +2.6%). However, annual COPD reviews fell 2.0% over 2023 to 2025 to 77.6% (England +2.8%). Asthma prevalence is 6.6% (3,127 patients; England 6.6%), where reviews rose +3.1% over 2023 to 2025 (England +4.4%) to 67.7%, leaving an estimated scale of 1,010 unreviewed patients. Slower review growth could reflect recall capacity constraints (unverified locally; a recall audit would test this). Prescribing of asthma management items was 2,087 per 1000 aged 5-19 (England 1,488).
Cancer register and children's immunisation
Cancer prevalence is 2.8% (1,409 patients; England 3.8%). In childhood immunisations (Q1 2025/26), 24-month 6-in-1 coverage reached 93.0% (England 92.2%). However, 12-month 6-in-1 was 80.4% (England 91.0%), 14.6 pp below the 95.0% target. At age 5, the 4-in-1 booster reached 70.4% (England 80.9%), 24.6 pp below target. In the same age-5 cohort, MMR dose 2 (76.1%) was 11.3 pp below dose 1 (87.4%). Cohorts differ; these do not show longitudinal dropout.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
Across NHS Greater Manchester ICB in 2022, 55.6% of cancers with a known stage (6,491 of 11,679) were diagnosed at stage 1 or 2 (England 55.3%), 19.4 percentage points below the 75.0% national ambition by 2028. Known-stage coverage was 70.8% (11,679 of 16,492; England 67.0%), leaving 2,268.2 extra cases needed to reach 75.0%. Staging data was not captured at PCN level. PCN breast screening coverage is 50.8% (England 69.9%, Manchester (LAD) 59.3%), despite a +31.5% three-year rise (2023 to 2024; England +8.4%), with Charlestown Md at 37.7%, Fernclough Surgery at 41.7%, and Beacon Medical Centre at 48.7%.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At Manchester University NHS Foundation Trust, the 62-day referral to treatment standard stood 12.2 percentage points below the 85.0% standard. The 28-day faster diagnosis standard was 5.1 percentage points above the 75.0% standard, and the 31-day standard was 3.5 percentage points below the 96.0% standard. For NHS Greater Manchester Integrated Care Board, the 62-day standard was 9.3 percentage points below the 85.0% standard, the 28-day standard was 4.5 percentage points above 75.0%, and the 31-day standard was 0.5 percentage points above 96.0%. These trust and ICB figures describe the wider system; PCN waiting times were not captured.
| Pathways within standard (%) | Manchester | Northern Care Alliance | Tameside and Glossop Integrated Care | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.06 | 75.20 | 82.48 | 79.53 | 79.32 |
| 31-day treatment (96%) | 92.54 | 94.54 | 96.25 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 72.85 | 78.65 | 76.77 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Manchester | Northern Care Alliance | Tameside and Glossop Integrated Care | England |
|---|---|---|---|---|
| MRI | 11.68 | 5.09 | 0.00 | 21.40 |
| CT | 14.66 | 4.10 | 0.18 | 9.92 |
| Echocardiography | 4.91 | 31.48 | 0.00 | 28.48 |
| Colonoscopy | 4.51 | 40.04 | 1.51 | 30.83 |
| Gastroscopy | 29.35 | 36.48 | 5.45 | 29.02 |
| All 15 DM01 tests | 8.98 | 15.71 | 0.80 | 23.14 |
| Community services activity | Manchester residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 96,995 | 573,310 |
| Referrals | 20,270 | 94,470 |
| Patients with a contact | 31,040 | 183,535 |
Community services (residents of Manchester), Jun 2026 (provisional). In the Community Services Dataset for June 2026 (provisional), adults aged 65 and over accounted for 43.3% of community contacts among Manchester local authority residents (42,015 of 96,995 contacts). Provider-specific and PCN-level community activity data were not captured; this describes borough-level activity rather than PCN performance.
Practice variation and patient experience
Personalised care adjustment rates range from 5.8% to 13.7% across practices in 2025/26
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Beacon | 105 | 96.6 | 76.8% | 71.2% | 87.4% |
| Church View | 114 | 100.0 | 69.0% | 82.7% | 87.3% |
| Fernclough Surgery | 100 | 100.0 | 83.7% | 72.9% | 84.5% |
| Valentine | 98 | 89.4 | 57.6% | 78.1% | 84.3% |
| Willowbank Surgery | 85 | 100.0 | 76.4% | 86.3% | 76.4% |
| Dam Head | 115 | 85.8 | 65.2% | 73.5% | 75.9% |
| Conran | 84 | 97.7 | 81.1% | 83.5% | 75.1% |
| Avenue | 93 | 84.2 | 47.6% | 77.7% | 71.9% |
| Charlestown Md | 92 | 77.3 | 47.1% | 80.2% | 70.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Twelve measures lag national growth despite heart failure reviews reaching 86.2%
Over 2023 to 2025, 12 measures trailed England's three-year change. Heart failure reviews grew +3.5% against +8.7% in England, despite high current achievement of 86.2% (England 78.5%). COPD reviews fell 2.0% (England +2.8%), and non-frail diabetes HbA1c control rose +0.9% (England +4.4%). Strengths include cervical screening (+5.8% vs England -1.0%) and mental health blood pressure checks (+7.3 pp vs England +4.4 pp). Slower review growth alongside high achievement may indicate follow-up capacity constraints rather than disengagement, which clinical workflow audits could clarify.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
COPD reviews
QRISK statin treatment
Diabetes HbA1c control
Asthma register
Breast screening (53-70)
Cervical screening
BP check (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Manchester (LAD) | Asset | PCN | Manchester (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 19 (500 beds) | n/a | Schools (catchment) | 62 | n/a |
| Children's centres | 5 | 34 | Places of worship | 40 | 289 |
| Libraries | 3 | 16 | Homelessness support (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 15 | 68 | Primary academies | 8 | 50 |
| Special schools | 1 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and recall
Asthma review coverage is 67.7% (England 65.7%), but 3-year growth (+3.1%, 2023 to 2025) lagged England (+4.4%), leaving an estimated 1,010 of 3,127 patients unreviewed. For discussion, the PCN could run single-template asthma recall and after-school review slots alongside inhaler prescribing checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Diabetes and hypertension titration recall
Non-frail diabetes HbA1c <= 58 mmol/mol is 53.6% (1,484 of 2,767 in 2024/25; England 57.4%) and hypertension treatment to target is 69.1% (England 70.3%). For discussion, the PCN could establish pharmacist-led recall and titration clinics for uncontrolled non-frail diabetes and hypertension patients. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Pre-school booster and MMR2 recall
In Q1 2025/26 (cohort 160), age-5 4-in-1 coverage is 70.4% (England 80.9%; ICB 80.5%) and MMR2 is 76.1% (England 82.8%), 11.3 pp below MMR1 (87.4%). For discussion, practices could run targeted age-5 recall with flexible clinic times and adapted invitations for overdue boosters. Moderate effort to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Culturally tailored health outreach (p2) | Black / African / Caribbean / Black British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Differentiated Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Smoking cessation support review (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension review and titration clinics (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool booster recall outreach (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted breast screening recall outreach (p7) | Breast screening coverage: aged 53 to 70 years old | — | PCN |
| Option 1 · Structured asthma review and recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Diabetes and hypertension titration recall (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Pre-school booster and MMR2 recall (p12) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · MMR dose 2 coverage at age 5 · MMR dose 1 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
